PD-1.6 was prominently linked with AML risk, PD-L1 rs2890658 with NSCLC, HCC and BC risk, PD-L1 rs17718883 with HCC and GC risk, PD-L1 rs10815225 with GC risk, and PD-L1 rs2297136 with NSCLC and HCC risk. This evidence concerns the gene RPL17 and breast cancer.